Simplify Logo

Full-Time

Staff Accountant

Posted on 9/3/2024

Umoja Biopharma

Umoja Biopharma

201-500 employees

Develops in vivo CAR T-cell therapies

Biotechnology
Healthcare

Compensation Overview

$80k - $97kAnnually

Entry, Junior

Lafayette, CO, USA

Category
Auditing
Cost Accounting
Financial Accounting
Accounting
Requirements
  • Masters or Bachelor’s in Accounting, Finance, or related field with 0+/2+ years of experience respectively
  • Proven understanding of basic accounting principles
  • Detail oriented with the ability to identify and resolve complex issues or problems
  • Ability to work independently, but also support the team as needed
  • Advanced Excel and Office 365 skills
Responsibilities
  • Timely and accurate monthly close process, including the preparation of supporting schedules and related analysis to ensure the accurate compilation and reporting of financial data in accordance with US GAAP and SEC requirements
  • Prepare journal entries, balance sheet reconciliations, maintain fixed asset schedule, maintain prepaid expenses schedule, and administer travel and expense reimbursement system
  • Partner with internal project managers and external service providers to determine appropriate accruals and expense recognition for R&D and Clinical projects
  • Support annual financial statement audits, quarterly reviews, and other audits as required
  • Perform internal controls and ensure compliance with SOX
  • Actively participate in cross-functional projects to represent our department’s needs/requirements
  • Take ownership of process improvements. Document business processes and assess current processes for efficiency
  • Ensure compliance with relevant laws and regulations and integrity of financial data
  • Support the end-to-end Accounts Payable process, including accurate postings, vendor statement reconciliation, payment batches, vendor disputes, cash disbursement reviews, and vendor master data review
  • Research and resolve invoice discrepancies and escalate as needed to ensure timeliness of payments
  • Partner with Senior Accounts Payable Specialist in preparing monthly accruals and account reconciliations
  • Additional assignments or projects as needed

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to other treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to enhance cancer treatment through effective use of the immune system.

Company Stage

Series B

Total Funding

$271M

Headquarters

Seattle, Washington

Founded

2019

Growth & Insights
Headcount

6 month growth

6%

1 year growth

15%

2 year growth

51%
Simplify Jobs

Simplify's Take

What believers are saying

  • The collaboration with AbbVie, valued at up to $1.44 billion, provides substantial financial backing and validation of Umoja's technology.
  • Umoja's appointment of experienced executives like Britton Russell as CFO indicates strong leadership capable of guiding the company through growth phases.
  • Being recognized as one of the thriving biotechs in Seattle underscores Umoja's prominence and potential in the biotech industry.

What critics are saying

  • The success of Umoja's in vivo CAR T-cell therapies is still contingent on clinical trial outcomes, which carry inherent uncertainties.
  • The competitive landscape in immunotherapy is intense, with numerous companies vying for market share, which could impact Umoja's growth.

What makes Umoja Biopharma unique

  • Umoja Biopharma's in vivo approach to reprogramming T cells is a significant departure from traditional ex vivo methods, offering a potentially more efficient and scalable solution.
  • Their proprietary CAR T-cell gene therapy platform is designed to be off-the-shelf, allowing for faster production and distribution compared to customized therapies.
  • Strategic partnerships with major players like AbbVie highlight Umoja's innovative edge and potential for significant market impact.
INACTIVE